Arca
Skip to content
Tools
Tools

Influenza

Drug research and approvals for influenza: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 133 studies of influenza are recruiting on ClinicalTrials.gov, Health Canada has authorized 47 drug trials for it since 2013, and the EU has 18 authorised medicines for it.

  • Recruiting worldwide: 133
  • Trials authorized in Canada: 47
  • FDA orphan approvals: 0
  • EU medicines: 18

Recruiting now

Newest posted first, of 133 recruiting on ClinicalTrials.gov ↗

How its trials ended

2,105 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 638 whose ending is known, 75% met their primary endpoint, 6% missed it and 19% stopped early.

  • Completed, result not reported1,16455%
  • Met its primary endpoint48023%
  • Ongoing1638%
  • Status unknown1407%
  • Stopped: other or unclear744%
  • Missed its primary endpoint392%
  • Stopped: enrollment or feasibility181%
  • Stopped: lack of efficacy131%
  • Stopped: sponsor or business decision9<1%
  • Stopped: funding4<1%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 47; search them all in Canada trials
Sep 16, 2026“a phase 3 randomized, observer-blind, controlled study to evaluate the clinical efficacy of an mrna-based seasonal influenza vaccine in older adults =65 years…Flu seasonal mRNA vaccine (GSK4382276A)GSKOngoing
Aug 31, 2026Safe (self-administration of flumist to improve uptake: a household-based cluster randomized trial)FlumistMcMaster UniversityPending
Feb 5, 2026A randomized, observer-blind, adaptive, active comparator-controlled, dose-ranging, multicenter, safety, tolerability, and immunogenicity phase 1/2 study of a…Trivalent virus-like particles (TVLP) influenza vaccineAramis BiotechnologiesOngoing
Nov 7, 2025A controlled human infection model for influenza: a phase 1 trial targeting a/H3N2 strain as a foundation for pandemic preparednessGood manufacturing practice-grade (GMP) RG-A/TEXAS/71/2017 (H3N2, clade 3C3A)Canadian Center for Vaccinology (Ccfv)Ongoing
Sep 24, 2025Pandemic influenza vaccine in organ transplantation (pivot trial: safety and immunogenicity of pandemic influenza vaccine in kdney transplant recipientsArepanrix H5N1University Health NetworkOngoing
Feb 25, 2025Adaptive platform trial of treatments for respiratory infections in community settings (treatresp)Baloxavir marboxil / OseltamivirUnity Health TorontoOngoing
Aug 4, 2023A phase 3, randomized, observer-blind, controlled, multicenter, clinical study to evaluate immunogenicity and safety of a high-dose MF59-adjuvanted…Aqivc hd / Fluad quadrivalent / Flublok quadrivalentSeqirus Uk LimitedClosed
Jul 7, 2023A phase 3 randomized double-blind controlled study to evaluate the immunogenicity, safety, and reactogenicity of EXPEC9V and high-dose quadrivalent influenza…VAC52416 (EXPEC9V)Johnson & JohnsonClosed
Oct 12, 2022A phase 3, randomized, observer-blind, active-controlled study to evaluate the safety and efficacy of MRNA-1010 candidate seasonal influenza vaccine in adults…MRNA-1010 / Fluarix quadrivalent influenza vaccineModernatx, Inc.Ongoing
Jun 23, 2022A phase 1, randomized, rater and subject blinded placebo controlled study to evaluate the safety, reactogenicity, tolerability and immunogenicity of a standard…VX-103Vaxess TechnologiesOngoing

Medicines authorised in the EU

Newest first; 15 of 18
Aug 20, 2026AujemfluInfluenza vaccine (surface antigen, inactivated, adjuvanted, prepared in cell culture)Seqirus Netherlands B.V.EMA ↗
Apr 20, 2026mCombriaxInfluenza mRNA vaccine; COVID-19 mRNA vaccineModerna Biotech Spain, S.L.EMA ↗
Mar 30, 2026SupemtekTrivalent influenza vaccine (recombinant, prepared in cell culture)Sanofi Winthrop IndustrieEMA ↗
Nov 15, 2024FlucelvaxInfluenza vaccine (surface antigen, inactivated, prepared in cell cultures)Seqirus Netherlands B.V.EMA ↗
Nov 15, 2024FluadInfluenza vaccine (surface antigen, inactivated, adjuvanted)Seqirus Netherlands B.V.EMA ↗
Jun 3, 2024FluenzInfluenza vaccine (live attenuated, nasal)AstraZeneca ABEMA ↗
Apr 19, 2024CelldemicZoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures)Seqirus Netherlands B.V.EMA ↗
Apr 19, 2024IncellipanPandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures)Seqirus Netherlands B.V.EMA ↗
Oct 9, 2023Zoonotic Influenza Vaccine SeqirusZoonotic influenza vaccine (H5N8) (surface antigen, inactivated, adjuvanted)Seqirus S.r.l.EMA ↗
Jan 7, 2021XofluzaBaloxavir marboxilRoche Registration GmbHEMA ↗
Nov 16, 2020Supemtek Tetra (previously Supemtek)Quadrivalent influenza vaccine (recombinant, prepared in cell culture)Sanofi Winthrop IndustrieEMA ↗
Apr 26, 2019DectovaZanamivirGlaxoSmithKline Trading Services LimitedEMA ↗
May 20, 2016Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune)Pandemic influenza vaccine (H5N1) (live attenuated, nasal)AstraZeneca ABEMA ↗
May 22, 2014EbilfuminOseltamivir · genericActavis Group PTC ehfEMA ↗
Nov 28, 2010AflunovZoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)Seqirus S.r.l.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.